Company profile for Athenex

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Our mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. We have generated our clinical product candidates through our Orascovery and Src Kinase Inhibition research platforms, which are based on our understanding of huma...
We are a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Our mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. We have generated our clinical product candidates through our Orascovery and Src Kinase Inhibition research platforms, which are based on our understanding of human absorption biology and novel approaches to inhibiting kinase activity, respectively.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Conventus Building 1001 Main Street Suite 600 Buffalo, New York 14203
Telephone
Telephone
(1) 716.427.2950
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Athenex files for bankruptcy, seeks buyer for cell therapy unit
Athenex files for bankruptcy, seeks buyer for cell therapy unit

15 May 2023

// Nick Paul Taylor FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/car-crash-athenex-files-bankruptcy-seeks-buyer-natural-killer-cell-therapy-unit

Nick Paul Taylor FIERCE BIOTECH
15 May 2023

https://www.reuters.com/markets/deals/drugmaker-athenex-voluntarily-files-us-chapter-11-proceedings-2023-05-14/

REUTERS
14 May 2023

https://www.prnewswire.com/news-releases/pine-pharmaceuticals-assumes-athenexs-503b-business-preserving-over-50-jobs-expanding-its-product-offerings-and-serving-hospitals-and-health-systems-nationwide-301814647.html

BUSINESSWIRE
03 May 2023
Athenex's cash dries up as it faces clinical hold, creditors
Athenex's cash dries up as it faces clinical hold, creditors

21 Mar 2023

// Gabrielle Masson FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/athenexs-cash-dries-it-faces-patient-death-fda-hold

Gabrielle Masson FIERCE BIOTECH
21 Mar 2023

https://www.globenewswire.com/news-release/2023/03/20/2630211/0/en/Athenex-Provides-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Business-Update.html

GLOBENEWSWIRE
20 Mar 2023
Athenex Announces a Reverse Stock Split
Athenex Announces a Reverse Stock Split

14 Feb 2023

// GLOBENEWSWIRE

https://www.globenewswire.com/news-release/2023/02/14/2607545/0/en/Athenex-Announces-a-Reverse-Stock-Split.html

GLOBENEWSWIRE
14 Feb 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty